Valeria Magarotto

2.9k total citations · 1 hit paper
32 papers, 837 citations indexed

About

Valeria Magarotto is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Valeria Magarotto has authored 32 papers receiving a total of 837 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Hematology, 19 papers in Molecular Biology and 15 papers in Oncology. Recurrent topics in Valeria Magarotto's work include Multiple Myeloma Research and Treatments (29 papers), Protein Degradation and Inhibitors (13 papers) and Cancer Treatment and Pharmacology (10 papers). Valeria Magarotto is often cited by papers focused on Multiple Myeloma Research and Treatments (29 papers), Protein Degradation and Inhibitors (13 papers) and Cancer Treatment and Pharmacology (10 papers). Valeria Magarotto collaborates with scholars based in Italy, United States and France. Valeria Magarotto's co-authors include Antonio Palumbo, Mario Boccadoro, François Lokiec, Franck Morschhauser, Lionel Karlin, Carmen Kahatt, Thierry Façon, Emanuele Zucca, Florence Broussais and Patrice Herait and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of the New York Academy of Sciences.

In The Last Decade

Valeria Magarotto

32 papers receiving 823 citations

Hit Papers

Bromodomain inhibitor OTX015 in patients with lymphoma or... 2016 2026 2019 2022 2016 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
    2016 328 citations Sandy Amorim, Anastasios Stathis et al. The Lancet Haematology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Valeria Magarotto Italy 12 669 565 345 61 47 32 837
Young Trieu Canada 13 561 0.8× 525 0.9× 335 1.0× 93 1.5× 79 1.7× 28 728
Mary McKenney United States 8 655 1.0× 769 1.4× 411 1.2× 124 2.0× 59 1.3× 11 871
Ying-Ming Jou United States 6 353 0.5× 349 0.6× 439 1.3× 77 1.3× 44 0.9× 8 631
Jessica Anderson United States 3 765 1.1× 682 1.2× 406 1.2× 137 2.2× 103 2.2× 5 1.0k
Marcy K. Vallone United States 8 748 1.1× 466 0.8× 335 1.0× 83 1.4× 77 1.6× 14 904
Annemiek Broijl Netherlands 13 463 0.7× 545 1.0× 403 1.2× 70 1.1× 32 0.7× 50 710
Claudia E. Paba‐Prada United States 12 462 0.7× 470 0.8× 305 0.9× 146 2.4× 100 2.1× 27 658
Claudius Rudin United Kingdom 7 352 0.5× 500 0.9× 532 1.5× 73 1.2× 73 1.6× 16 845
Jose Estevam United States 11 566 0.8× 627 1.1× 361 1.0× 82 1.3× 30 0.6× 16 754

Countries citing papers authored by Valeria Magarotto

Since Specialization
Citations

This map shows the geographic impact of Valeria Magarotto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Valeria Magarotto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Valeria Magarotto more than expected).

Fields of papers citing papers by Valeria Magarotto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Valeria Magarotto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Valeria Magarotto. The network helps show where Valeria Magarotto may publish in the future.

Co-authorship network of co-authors of Valeria Magarotto

This figure shows the co-authorship network connecting the top 25 collaborators of Valeria Magarotto. A scholar is included among the top collaborators of Valeria Magarotto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Valeria Magarotto. Valeria Magarotto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Molica, Stefano, Potito Rosario Scalzulli, Lydia Scarfò, et al.. (2021). The Use of Ibrutinib in Italian CLL Patients Treated in a Real-World Setting (EVIDENCE): A Preliminary Report. Blood. 138(Supplement 1). 4684–4684. 2 indexed citations
3.
Amorim, Sandy, Anastasios Stathis, Mary Gleeson, et al.. (2016). Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. The Lancet Haematology. 3(4). e196–e204. 328 indexed citations breakdown →
4.
Bringhen, Sara, Valeria Magarotto, Anna Marina Liberati, et al.. (2016). A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients. Blood. 128(22). 1145–1145. 7 indexed citations
5.
6.
Larocca, Alessandra, Vittorio Montefusco, Sara Bringhen, et al.. (2013). Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood. 122(16). 2799–2806. 66 indexed citations
7.
Klepin, Heidi D., David A. Rizzieri, Antonio Palumbo, Valeria Magarotto, & Barbara Eichhorst. (2013). Individualizing Treatment Decisions for Older Adults with Hematologic Malignancies. American Society of Clinical Oncology Educational Book. 208–219. 5 indexed citations
8.
Bringhen, Sara, et al.. (2013). The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma. Expert Opinion on Drug Metabolism & Toxicology. 9(10). 1371–1379. 16 indexed citations
9.
Klepin, Heidi D., David A. Rizzieri, Antonio Palumbo, Valeria Magarotto, & Barbara Eichhorst. (2013). Individualizing Treatment Decisions for Older Adults with Hematologic Malignancies. American Society of Clinical Oncology Educational Book. 33. 208–219. 9 indexed citations
10.
Hunsucker, Sally A., Valeria Magarotto, Deborah J. Kuhn, et al.. (2011). Blockade of interleukin‐6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. British Journal of Haematology. 152(5). 579–592. 63 indexed citations
11.
Palumbo, Antonio, Alessandra Larocca, Maurizio Genuardi, et al.. (2010). Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica. 95(7). 1144–1149. 31 indexed citations
12.
Palumbo, Antonio, Alessandra Larocca, Grazia Sanpaolo, et al.. (2010). Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. Leukemia. 24(5). 1037–1042. 32 indexed citations
13.
Magarotto, Valeria & Antonio Palumbo. (2009). Evolving Role of Novel Agents for Maintenance Therapy in Myeloma. The Cancer Journal. 15(6). 494–501. 4 indexed citations
14.
Palumbo, Antonio, Patrizia Falco, Antonietta Falcone, et al.. (2009). Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results. Clinical Lymphoma & Myeloma. 9(2). 145–150. 30 indexed citations
15.
Palumbo, Antonio, Patrizia Falco, Grazia Sanpaolo, et al.. (2008). Combination of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial. Blood. 112(11). 868–868. 6 indexed citations
16.
Larocca, Alessandra, Federica Cavallo, Valeria Magarotto, et al.. (2008). Defibrotide: a review on clinical use and future development. Expert Opinion on Biological Therapy. 8(8). 1201–1212. 4 indexed citations
17.
Palumbo, Antonio, Francesca Gay, Sara Bringhen, et al.. (2008). Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Annals of Oncology. 19(6). 1160–1165. 85 indexed citations
18.
Palumbo, Antonio, Grazia Sanpaolo, Alfredo Falcone, et al.. (2008). Lenalidomide, melophalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. 256–256. 2 indexed citations
19.
Palumbo, Antonio, Valeria Magarotto, Francesca Gay, et al.. (2008). Update on Recent Developments for Patients with Newly Diagnosed Multiple Myeloma. Annals of the New York Academy of Sciences. 1138(1). 19–21. 1 indexed citations
20.
Palumbo, Antonio, Alessandra Larocca, Cecilia Rus, et al.. (2007). A Phase I/II Trial on Melphalan, Prednisone, Thalidomide and Defribotide Combination in Relapsed/Refractory Multiple Myeloma Patients.. Blood. 110(11). 2715–2715. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Young Trieu Breakdown of academic impact, for papers by Mary McKenney Breakdown of academic impact, for papers by Ying-Ming Jou Breakdown of academic impact, for papers by Jessica Anderson Breakdown of academic impact, for papers by Marcy K. Vallone Breakdown of academic impact, for papers by Annemiek Broijl Breakdown of academic impact, for papers by Claudia E. Paba‐Prada Breakdown of academic impact, for papers by Claudius Rudin Breakdown of academic impact, for papers by Jose Estevam
Rankless by CCL
2026